Dr. Trevor Martin co-founded Mammoth Biosciences with the mission to enable the next generation of CRISPR-based transformative products across therapeutics and diagnostics. Areas of focus include a novel class of affordable, effective, and rapid CRISPR-enabled molecular diagnostics that allow individuals worldwide to better understand their health and novel families of nano-sized CRISPR proteins including Cas14 and Cas⏀ that can enable in-vivo editing. Trevor earned his BA from Princeton University and his PhD in Biology from Stanford. His scientific work has been featured in outlets including FiveThirtyEight and The Atlantic. He is the featured healthcare honoree on the Forbes 30 Under 30 list, is on Fortune’s 40 Under 40 list, and is an EY Entrepreneur of the Year 2021.

最热内容

Health and Healthcare Systems

5 things to know about CRISPR and gene editing in the COVID era

One of the most common misconceptions about CRISPR is that it’s only useful for gene editing. In reality, CRISPR can be used for a wide variety of non-gene editing applications, ranging f...

2020年08月12日